You've always wanted to grow those perky cuppy breast, order your Estrogen pills and Injectables today to begin your transition and transformation journey 📦🚚. Telegram- t.me/VitaFemme Delivery worldwide 🌍 🚚

“Effortless beauty” now requires injectables and cinematic lighting. #beautytrends

4. Le cocktail Müller - PRP, Actovegin (a fait mettre Armstrong en examen), ozone, anesthésiques, AINS… Müller‑Wohlfahrt mélange des traitements injectables controversés mais licites. Il a soigné le Bayern, l’équipe d’Allemagne et Usain Bolt même après sa carrière.

#52weekhighstock #Breakoutstocks Thread below part 3 Keep sl last week low if taking positions on Monday For swing trading 🔖🔖🔖🔖 Caplin Point Laboratories Limited is a fully integrated, rapidly growing Indian pharmaceutical company headquartered in Chennai, Tamil Nadu. Established in 1990, it specializes in manufacturing and developing finished formulations, Active Pharmaceutical Ingredients (APIs), and injectables. The company predominantly serves emerging markets like Latin America and Africa while also expanding into regulated markets such as the USA and EU.

🚀 Kabra Drugs Secures ₹200 Crore Pharma Project in Chhattisgarh! | MCap 50.81 Cr - Kabra Drugs Ltd. received LOI for a ₹200 Crore pharmaceutical manufacturing project in Nava Raipur Pharma Park, Chhattisgarh. - The project is expected to generate ~250 direct and indirect jobs. - Aligns with company’s long-term growth strategy, focusing on quality and innovation. - Will expand manufacturing footprint and operational capabilities. - Benefits from state government policies and incentives. - Kabra Drugs specializes in specialty formulations, injectables, and APIs. - Project pending definitive agreements and approvals. Disc: Information provided in above tweet can be inaccurate, verify through the source i.e. attached image(s) & in reply before making any investment decision.

📊 KABRA DRUGS LTD - 524322 | 🪒 Press Release / Media Release Kabra Drugs Ltd has received a letter of intent from the government of Chhattisgarh for a ₹200 crore pharmaceutical manufacturing project at Nava Raipur Pharma Park. This initiative is a key component of the company's long-term expansion strategy, aimed at enhancing its manufacturing capabilities and footprint in the pharmaceutical sector. Company Snapshot: Kabra Drugs Ltd is a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs. Key Highlights: Project Investment: - Proposed investment of approximately ₹200 crore. - Location: Nava Raipur Pharma Park, Chhattisgarh. Employment Generation: - Expected to create approximately 250 direct and indirect job opportunities. Strategic Significance: - Marks a significant milestone in Kabra Drugs Ltd's expansion strategy. - Aims to strengthen the company's presence in the pharmaceutical sector. Regulatory Framework: - The investment proposal is subject to execution of definitive agreements and receipt of necessary approvals and sanctions. Executive quote: Mr. Nanjappan Aravind, Managing Director, stated, "The proposed ₹200 crore investment at Nava Raipur Pharma Park is aligned with our vision of expanding our manufacturing capabilities." Optional closing line: This project is expected to leverage state government policies and incentives, further positioning Kabra Drugs Ltd for growth in the pharmaceutical industry. 💰 CMP: ₹23.63 ( 10.27%) 🏢 MCap: ₹56.0 Cr 🌐Details: tinyurl.com/24f5xkwv ⚡️Instant stock alerts on WhatsApp - Try FREE 👉 speedystox.com

Didier Raoult et Remi Kasprzyk sont deux véritables demi-frères ... deux parfaits VRP de Merck/MSD et de son Gardasil (1), ainsi que deux promoteurs des injections anti-Covid-19 de Pfizer et consorts (2) ! 1. Le vendeur de Gardasil, Rémi Kasprzyk youtube.com/watch?v=xlqm3p7F… Le vendeur de Gardasil, Didier Raoult youtu.be/zAampntyD6k?si=thKW… 2. Le fait est que Didier "Gardasil" Raoult et Remi "Gardasil" Kasprzyk sont exactement sur la même ligne; avant sa retraite, Didier Raoult était au service de complices de Pfizer et de Moderna: les industriels Alexandre et Alain Mérieux. La seule distinction à faire entre eux deux, parfaits collabos de l'industrie des produits injectables, est que l'auproclamé Mbappé de la microbiologie a été déguisé en opposant à cette industrie de mort. x.com/Arreter_Fischer/status…

Dear $ABVX friends. |🚨 #BREAKING | In my previous post, I noted that icotrokinra 400 mg outperforms obefazimod 50 mg on clinical remission in an indirect comparison. I'm not factoring in obefazimod 25 mg since it failed to meet the primary endpoint in the ABTECT-2 trial. ✅ Icotrokinra 400 mg (30.2%) vs. placebo (11.1%). difference, 19.1 percentage points. At week 12. 🟥 50 mg obefazimod (21.7%) vs. placebo (2.5%). difference, 19.2 percentage points [ABTECT-1]. Meanwhile, in the ABTECT-2, 50 mg obefazimod (19.8%) vs. placebo (6.3%). difference, 13.5 percentage points. Obefazimod 25 mg did not demonstrate efficacy (ABTECT-2; p=0.1034). At week 8. But more importantly, check out Protagonist's update on the commercialization of ICOTYDE [icotrokinra] at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. 1️⃣"The early indications regarding the launch are incredibly positive." 2️⃣ "During their first earnings call, which was April 14th, they claimed more than 1,000 prescribers. Yesterday, they shared it's more than 4,500 prescribers. Really, they are getting the market share both from experienced and naive populations and the switch from other orals and injectables to orals." 3️⃣ "J&J is saying that Icotyde could become one of its most successful drug in the history and potentially grow now greater than $10 billion at peak sales." And unlike obefazimod 50 mg, which may receive a black box warning due to 'Possibly Related' malignancy cases in the ABTECT maintenance trial, icotrokinra shows no such signals, and therefore carries no black box warning. That's a big deal, and it's a major reason why icotrokinra has a real shot at hitting J&J's projected $10B peak sales target. Also posting later today: $TAK's Entyvio, one of the gold standards in IBD treatment, has been selected by CMS for Medicare price negotiations. And on top of that, on June 8th, the FDA accepted $ALVO $TEVA Alvotech/Teva's BLA for AVT16, a proposed interchangeable biosimilar to Entyvio, meaning UC and Crohn's patients may soon have access to a more affordable treatment option.

Le fait est, M. Kasprzyk, que Didier "Gardasil" Raoult, est exactement sur la même ligne que vous; avant sa retraite, il était au service de complices de Pfizer et de Moderna: les industriels Alexandre et Alain Mérieux (1). La seule distinction à faire entre vous deux, parfaits collabos de l'industrie des produits injectables, est que lui a été déguisé en opposant à cette industrie de mort (2). 1. "IHU-MI ou IHU-IM, messieurs Alain Mérieux et Didier Raoult ?" alainschollaert.wordpress.co… 2. "Didier Raoult: “les femmes enceintes devraient se faire vacciner… avant d’être enceintes” !" "Convaincre des citoyens honnêtes qu’un dangereux Cheval de Troie est un de leurs meilleurs alliés et qu’il les représente parfaitement pour faire face, par exemple, aux organisateurs du génocide “vaccinal” en cours… il n’y a rien de plus enfantin !" alainschollaert.wordpress.co…

$HIMS --- On June 2, $HIMS officially announced it has completed the full acquisition of Australian digital health giant Eucalyptus — owner of leading weight management brand Juniper. The deal not only gives HIMS its first entry into Japan, Germany, Canada and Australia, but also immediately expands its subscriber base materially. $HIMS has also struck a landmark GLP-1 strategic partnership with Novo Nordisk — an epic, game-changing catalyst. This resolves the long-running legal and licensing disputes that had weighed heavily on the stock, and represents a decisive win for HIMS. The two companies have buried the hatchet: Novo Nordisk's FDA-approved blockbuster weight loss drugs (including Wegovy and Ozempic) will now be distributed directly on the HIMS platform. This instantly transforms HIMS from a controversial compounded medication provider operating on regulatory fringes into a legitimate, official partner of the world's largest weight loss drug maker. On June 4, the company appointed Dr. Anant Vinjamoori as its new Chief Medical Officer, as it pushes into cutting-edge areas including longevity medicine and multi-cancer early detection (MCED). Meanwhile, its ongoing $250 million share repurchase program continues to provide strong downside support for the stock. 1. The Ultimate Subscription Model Solution for Digital Healthcare Traditional healthcare is plagued by cumbersome processes and social stigma around sensitive conditions (hair loss, sexual health, mental health, obesity). HIMS hits the pain point of modern consumers head-on with highly personalized, frictionless online consultations and direct-to-door medication delivery. Exceptional user stickiness: As of Q1 2026, active subscribers on the platform have surpassed 2.6 million (up 9% YoY). High margins compounding flywheel: ~75% gross margins give it ample capital for marketing spend. As user retention improves, customer acquisition cost (CAC) steadily dilutes, unlocking dramatic operating leverage over time. 2. GLP-1 Weight Loss Drugs as the Second Growth Curve Against a backdrop of global GLP-1 supply shortages, HIMS provides a critical, high-demand distribution channel. With the regulatory tailwind for compounded medications facing FDA re-evaluation risk, HIMS has pivoted nimbly: it now offers personalized non-GLP-1 oral weight loss formulations, and has locked in supply of legitimate branded injectables via its Novo Nordisk partnership — directly riding the largest weight loss drug boom in human history. 3. Global, Multi-Dimensional Consumer Health Ecosystem By acquiring Eucalyptus, HIMS is replicating its U.S. success model globally while expanding into new verticals. What started as a niche men's health platform is now evolving into a comprehensive global consumer healthcare platform spanning full-body weight management, dermatology, early cancer screening and routine wellness, powered by partnerships with 10 leading health brands including Dexcom, MyFitnessPal and HelloFresh.

Cheaper than in the U.S. especially 9 mg. However, about the same priced as injectables, yes, which is probably the explanation to why it's cheaper than in the U.S.

They produce injectables .

Are you ready to master the art of injectables? 💉 Our very own Johanna Duarte, MPAS, PA-C, is inviting you to an elite learning experience: the Introduction to Neurotoxin & Fillers Master Class. Learn directly from Award-Winning Master Injector JAC...

Parmi ces 15 jeunes pousses, deux sont implantées en France : Bubble Robotics, à l’origine de petits appareils de surveillance sous-marine, et Robeauté, qui développe des micro-robots injectables dans le cerveau. usine-digitale.fr/intelligen…

💉 Did you know? Long-acting injectables (LAIs) deliver mental health medication slowly over time — often the same meds as daily pills, with fewer doses to remember. For more info, use the QR code above, the link below, or reach out to your provider. 🔗 buff.ly/rGVQRwC

Losing weight can be a transformative journey, but it may leave unexpected souvenirs like hollowed cheeks or under-eye areas. Non-invasive treatments can replenish fullness brnw.ch/21x3k8B #SkinOnline #SkinOnlineBlog #YouthfulContours #injectables #DermalVolumisers

You've always wanted to grow those perky cuppy breast, order your Estrogen pills and Injectables today to begin your transition and transformation journey 💉 💦 📦 💊 💉 🚚 💊 💉 🚚